Hepatic immune prognostic index as a prognostic biomarker in hepatocellular carcinoma patients treated with transarterial chemoembolization
Therapeutic Advances in Medical Oncology
Published online on May 14, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Due to hepatocellular carcinoma (HCC) heterogeneity, the prognosis of patients who receive transarterial chemoembolization (TACE) treatment varies greatly. A thorough pre-treatment assessment is necessary to identify suitable candidates for ...
Background:Due to hepatocellular carcinoma (HCC) heterogeneity, the prognosis of patients who receive transarterial chemoembolization (TACE) treatment varies greatly. A thorough pre-treatment assessment is necessary to identify suitable candidates for ...